Sunshine Biopharma Receives Notification Letter From The Nasdaq Stock Market Granting The Company's Request For An Exception Until August 26, 2024, To Regain Compliance
$SBFM
Biotechnology: Pharmaceutical Preparations
Health Care
On June 28, 2024, Sunshine Biopharma, Inc. (the "Company") received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"), informing the Company that the Nasdaq Hearings Panel has granted the Company's request for an exception until August 26, 2024, to regain compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2)